RUTHERFORD, N.J., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, announces the addition of Christopher Mitton as Director of National Account Development and Sales Operations. Mr. Mitton will lead the national expansion of CGI's Expand Dx™ program. Expand Dx™ is designed to increase outreach and patient value for community hospitals and labs by expanding their cancer diagnostic capabilities through the addition of new testing methodologies and collaborative services.
Mr. Mitton brings more than a decade of diagnostics sales experience to CGI. Most recently he led the North American sales of leukemia and solid tumor molecular diagnostic tests for Qiagen, a mid-cap NASDAQ-listed company and leading global provider of sample and assay technologies. Mr. Mitton's previous diagnostic sales roles include Ipsogen, Bayer HealthCare, Abbott Diagnostics and BioChem Immunosystems. Throughout his career, Mr. Mitton has been consistently recognized for meeting and exceeding revenue targets, strong strategic vision and planning, and developing and motivating a top producing team. He earned his bachelors of science in molecular biology at Florida A&M University.
"I'm excited to join the CGI team due to the organization's growth trajectory, proprietary technologies, and dedication to the hematologic and urogenital cancer market," stated Mr. Mitton. "CGI's innovative Expand Dx program addresses a market in need of genomic testing solutions and will deliver a comprehensive, world-class expansion of molecular pathology in community laboratories to improve patient management. I am honored to be joining such a highly accomplished, visionary company."
CGI continues to expand its sales force and reached its 2013 goal of 14 professionals. Mr. Mitton will lead a regionally distributed team and focus on a campaign to expand the use of the Company's proprietary testing solutions amongst community hospitals and labs. With a successful track record of increasing test adoption in place, Expand Dx™ is an ongoing priority for CGI, and additional sales team expansion in 2014 is expected to accelerate test volume and revenue growth.
"A major goal of CGI is to bring DNA-based cancer testing to the community setting," stated Panna Sharma, president and CEO of CGI. "The leadership, commitment to results and knowledge of the molecular market that Chris brings to CGI will help us drive adoption of genetic testing into the patient care cycle, where we can better help oncologists, pathologists and hospitals serve their patients by eliminating duplicate and unnecessary testing while providing earlier diagnosis, risk stratification and more appropriate treatment selection information. The Expand Dx program, which Chris will help further develop, will lead to significant reductions in cost of treatment and improved outcomes in community hospitals."
Jane Quigley, RN, senior principal at IMS Health, stated, "An estimated 80% of cancer care in the U.S. is carried out in [these] community-based oncology settings." ("Industry Confronts Healthcare's Changing Oncology Practices," Pharmaceutical Commerce, April 30, 2013).
The Expand Dx™ program is an initiative offered by CGI for the expansion of clinical services by joint collaboration with CGI Laboratories™. Expand Dx™ is designed to enhance and expand other laboratories' clinical offerings in cancer diagnostics and personalized cancer treatment by introducing new methodologies and proprietary disease-focused testing. Expand Dx™ works to build on laboratories' capabilities to increase efficiency and drive revenue to help them stay competitive and grow in today's evolving market. More information is available at: http://www.cancergenetics.com/laboratory-services/cgi-expand-dx/
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.